KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.95

A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The PRIME Study.

Bernhard J Eigl, Arun Elangovan, Sunita Ghosh, Julian O Kim, John Thoms, Myriam Bouchard, Michael Peacock, Neil Fleshner, Holly Campbell, Eric Vigneault, Francois Vincent, Alan So, Fabio Cury, Harvey Quon, Ryan Carlson, Carole Lambert, Laurie Klotz, Kim Chi, Michael Brundage, Michael Pollak, Lisa Rebane, Leanne Chiu, Kerry S Courneya, Nawaid Usmani

J Urol 214(5) 496-508

PMID40711960
PMCID-
DOI10.1097/JU.0000000000004695
发表日期2025-07-25
入排依据:The trial is a Phase 3 randomized controlled trial in human oncology patients, but its primary and secondary outcomes are metabolic syndrome and related parameters (weight, waist circumference, HbA1c), not survival, progression, recurrence, death, or time-to-event efficacy outcomes required for eligibility.
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

PURPOSE: We investigated whether metformin decreases metabolic syndrome (MS) risk in patients with prostate cancer (PCa) receiving androgen deprivation therapy (ADT). MATERIALS AND METHODS: In this phase 3, multicenter, double-blind, randomized controlled trial, normoglycemic patients with PCa planned for at least 9 months of ADT were randomized 2:1 to receive metformin 850 mg or placebo twice daily orally for 18 months. The primary objective was to compare proportions of MS at 18 months between the study arms. RESULTS: Between July 2018 and November 2023, 166 patients were randomized. The trial closed prematurely on November 24, 2023, because of drug supply cessation and the planned enrollment numbers (n = 300) were not met. A total of 90 (metformin) and 45 patients (placebo) were analyzed in the final analysis. The median follow-up was 24 months (IQR: 19.5-36 months). Proportions of MS between metformin and placebo arms were 38/90 (42%) vs 26/45 (58%) at baseline (P = .09) and 40/73 (55%) vs 23/34 (68%) at 18 months (P = .2). Significant reductions in mean (SD) body weight occurred with metformin at 9 (-0.9 [4] vs +1.8 [3.8] kg; P < .001) and 12 months (-0.33 [3.9] vs +1.8 [3.9] kg; P = .004). Mean (SD) hemoglobin A1c was lowered with metformin at 9% (-0.02% [0.23%] vs +0.08% [0.26%]; P = .02) and 12 months (+0.03% [0.27%] vs +0.08% [0.27%]; P = .03). Significantly smaller increments in mean (SD) waist circumferences were noted with metformin at 9 (+0.8 [4.3] vs +2.9 [5.7] cm; P = .03), 12 (+1.9 [5.1] vs +3.3 [6] cm; P = .15), and 18 months (+1.8 [3.8] vs +3.8 [6.1] cm; P = .03). CONCLUSIONS: Metformin did not reduce the risk of MS in patients with PCa on ADT. However, significant improvements in body weight, waist circumference, and hemoglobin A1c suggest a potential role for metformin in reducing ADT-related complications.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。